BGB-16673 (BTK Degrader)

May 6, 2026 — BeOne Medicines Ltd. reported first-quarter 2026 financial results and business updates, highlighting continued growth driven mainly by BRUKINSA (zanubrutinib). Total revenue was $1.51B (+35% YoY), with net product revenue of $1.49B (+34%). GAAP operating income rose to $249.9M (from $11.1M) and GAAP net income to $227.4M (from $1.3M). Diluted GAAP EPS was $1.96 per ADS (non-GAAP $3.24), and free cash flow was $160.5M (vs. -$12.3M). Product performance included BRUKINSA global sales of $1.1B (+38%; U.S. $761M, +35%), TEVIMBRA (tislelizumab) $206M (+20%), and Amgen in-licensed products $142M (+25%); GAAP gross margin improved to 89% (from 85%).

BeOne raised FY2026 revenue guidance to $6.3–$6.5B and GAAP operating income to $750–$850M. Business updates included Japan orphan designation and filings for BRUKINSA in R/R MZL; sonrotoclax launch in China (R/R MCL and R/R CLL/SLL); FDA Priority Review acceptance for TEVIMBRA with ZIIHERA plus chemotherapy in first-line HER2+ GEA (HERIZON-GEA-01 overall survival benefit vs trastuzumab + chemo). BeOne also entered an exclusive option with Huahui Health for worldwide rights to HH160 (BON-110), a PD-1/VEGF-A/CTLA-4 trispecific antibody.